Turning biology into high-confidence, low-toxicity lead series.
CuraGenAI delivers synthesis-ready lead series to pharma and biotech partners. Our CureRX platform compresses target-to-lead discovery from years to weeks.
Selected therapeutic programs are advanced toward clinical translation through CuraGen Neuro Therapeutics, including a brain-directed ACAT1/SOAT1 program in glioblastoma.
Our Progress
AKR1C3, ACAT1, CD33
9 Lead Candidates
Generated and advancing
<12 weeks
Target to synthesis-ready leads (AKR1C3)
Discovery-collaboration lead IP owned by partners
CuraGen Neuro Therapeutics
CuraGen Neuro Therapeutics advances selected CNS and neuro-oncology programs toward clinical development. Its lead neuro-oncology program targets ACAT1/SOAT1-mediated cholesterol storage in recurrent/progressive glioblastoma using a brain-directed intranasal small-molecule approach. Independent published studies support SOAT1 as a metabolic vulnerability in GBM, and an FDA Type B pre-IND interaction has defined the core IND-enabling development path.
Program status: IND-enabling. Clinical efficacy in glioblastoma has not been established.
The CureRX Discovery Platform
Closed-loop small-molecule discovery from target definition to synthesis-ready lead series.
CureRX combines generative chemistry, multi-objective optimization, and reinforcement-learning cycles to deliver partner-grade candidates for experimental work.
Target Definition & Druggability Assessment
Generative Chemistry
de novo molecular design
Multi-Objective Optimization
potency, selectivity, safety, ADMET
Lead Delivery
synthesis-ready, experiment-feasible candidates
What Our Partners Receive
Optimized Lead Series
20–50 candidate molecules across multiple novel chemical scaffolds.
Multi-Parameter Optimization
Candidates optimized across potency, selectivity, ADMET, safety, and synthetic feasibility.
Discovery Data Package
Full molecular design library, predicted properties, optimization rationale, and prioritized synthesis candidates.
Experimental Readiness
Synthesis-feasible molecules prioritized for validation, with optional CRO partner access for in-vitro/in-vivo testing.
Why Partners Use CuraGenAI
Accelerate Cycle Time
Compress target-to-lead timelines from years to weeks.
Reduce Discovery Risk
Multi-objective optimization eliminates weak candidates early. Integrated ADMET prediction de-risks before synthesis.
Operate as an Extension of R&D
No need to build or maintain in-house AI discovery capability. CureRX operates as a seamless extension of partner R&D.
Generate Superior Candidates
Molecules optimized simultaneously across potency, selectivity, safety, and developability.